Risk based frameworks for approving AI tools inside QMS environments Risk based frameworks for approving AI tools inside QMS environments The integration of Artificial Intelligence (AI) and Machine Learning (ML) technologies into Good Quality Practices (GxP) quality systems is revolutionizing the pharmaceutical and biotechnology industries. However, this integration comes with its own set of regulatory challenges and considerations. Regulatory Affairs (RA) professionals must navigate the evolving landscape to ensure compliance while leveraging these advanced technologies to enhance quality and efficiency. This article provides a comprehensive regulatory explainer on FDA expectations for AI and ML in GxP quality systems. Regulatory Context…

Involving Quality and Regulatory Early in AI Proof of Concept Projects Involving Quality and Regulatory Early in AI Proof of Concept Projects The introduction of Artificial Intelligence (AI) and Machine Learning (ML) into Good Practice (GxP) quality systems represents a significant evolution in the pharmaceutical and biotech industries. Given the complexities involved, regulatory professionals must understand the expectations set forth by regulatory agencies such as the FDA, EMA, and MHRA. Early involvement of quality and regulatory affairs in AI proof of concept projects is critical to ensuring compliance and addressing potential deficiencies proactively. Context In GxP settings, AI systems can…

Designing Internal Policies for Responsible AI in GMP Quality Operations Designing Internal Policies for Responsible AI in GMP Quality Operations Introduction As the biopharmaceutical industry increasingly adopts Artificial Intelligence (AI) and Machine Learning (ML) technologies, understanding regulatory expectations is critical for maintaining compliance within Good Manufacturing Practices (GMP) quality systems. This article provides a comprehensive guide on the FDA’s expectations regarding the use of AI in GxP operations, drawing connections to relevant regulations, guidelines, and best practices. Regulatory Context for AI in GxP Quality Systems The integration of AI/ML technologies into GxP operations necessitates a thorough understanding of the regulatory…

Global convergence of FDA, EMA and MHRA positions on AI in GxP systems Global convergence of FDA, EMA and MHRA positions on AI in GxP systems Artificial Intelligence (AI) and Machine Learning (ML) are changing the landscape of Quality Systems (GxP) within the pharmaceutical and biotech industries. Regulatory expectations set forth by the FDA, EMA, and MHRA provide essential guidelines to ensure that AI and ML implementations maintain the integrity, safety, and efficacy of drug products. This regulatory explainer manual delves into the FDA’s expectations for AI in GxP quality systems, elucidating the relevant regulations and guidelines, decision-making points, and…

Training QA and RA teams on emerging FDA thinking for AI and ML Training QA and RA teams on emerging FDA thinking for AI and ML The integration of Artificial Intelligence (AI) and Machine Learning (ML) into Good Practice (GxP) quality systems has transformed various dimensions of pharmaceuticals and biotech industries. Regulatory Affairs (RA) professionals must remain at the forefront of these advancements, particularly concerning the expectations set forth by the U.S. Food and Drug Administration (FDA). This article serves as a comprehensive guide for training Quality Assurance (QA) and RA teams on FDA expectations for AI and ML in…

KPIs to track compliance and value of AI adoption in quality systems KPIs to Track Compliance and Value of AI Adoption in Quality Systems The advent of Artificial Intelligence (AI) and Machine Learning (ML) technologies in the pharmaceutical and biotech industries is transforming Quality Systems (QS) within Good Practices (GxP) ecosystems. Understanding the FDA expectations regarding AI use in GxP quality systems is crucial for compliance and ensuring the integration of responsible AI is effective. This manual provides an in-depth overview of key regulatory considerations, essential documentation, review processes, and the common deficiencies that may arise during regulatory inspections. Regulatory…

Using AI to Prioritize Deviations and Focus Investigations in GMP Plants Using AI to Prioritize Deviations and Focus Investigations in GMP Plants In the ever-evolving pharmaceutical and biotechnology sectors, the integration of Artificial Intelligence (AI) into Quality Management Systems (QMS) is revolutionizing processes such as deviation investigations and root cause analysis. This regulatory explainer manual delves into the strategic applications of AI-Enabled Deviation Investigations, offering insights into the regulatory context, documentation requirements, the review process, and common deficiencies faced when implementing AI solutions in compliance with FDA, EMA, and MHRA expectations. Regulatory Affairs Context The concept of integrating AI into…

Machine learning models for root cause analysis in quality investigations Machine Learning Models for Root Cause Analysis in Quality Investigations In the ever-evolving landscape of pharmaceutical and biotechnology industries, ensuring quality through robust regulatory affairs practices is critical. This article serves as a regulatory explainer manual focused on AI-enabled deviation investigations, examining how machine learning (ML) can be employed in effective root cause analysis, deviation triage, and improving Quality Management Systems (QMS) workflows. Context With the increasing adoption of artificial intelligence (AI) and machine learning in regulatory affairs and quality systems, pharmaceutical companies are turning towards these technologies to enhance…

Designing AI assisted deviation triage workflows inside your QMS Designing AI assisted deviation triage workflows inside your QMS In the rapidly evolving pharmaceutical and biotechnology sectors, regulatory compliance and quality assurance are paramount. Integrating artificial intelligence (AI) into quality management systems (QMS) offers significant advantages for managing deviations, investigations, and root cause analyses. Context Deviation investigations are critical within a QMS, serving to identify and resolve discrepancies that can impact product quality and compliance with regulatory standards. The evolving landscape of AI technologies—including machine learning (ML) and natural language processing (NLP)—enables more efficient workflows within the deviation management processes. Implementing…

Training Data Requirements for AI Tools that Classify GMP Deviations Training Data Requirements for AI Tools that Classify GMP Deviations The pharmaceutical industry is experiencing a transformative shift with the integration of artificial intelligence (AI) in various Quality Management System (QMS) workflows. AI-enabled deviation investigations leverage Machine Learning (ML) models to enhance efficiency in root cause analysis and deviation triage. This article serves as a comprehensive regulatory explainer manual, detailing the training data requirements for AI systems deployed to classify Good Manufacturing Practice (GMP) deviations. Regulatory Context AI technologies applied in pharmaceutical manufacturing and quality assurance are subject to a…